These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 6872420)

  • 1. Elimination of amphotericin B in impaired renal function.
    Morgan DJ; Ching MS; Raymond K; Bury RW; Mashford ML; Kong B; Sabto J; Gurr FW; Somogyi AA
    Clin Pharmacol Ther; 1983 Aug; 34(2):248-53. PubMed ID: 6872420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction.
    Mihindu JC; Scheld WM; Bolton ND; Spyker DA; Swabb EA; Bolton WK
    Antimicrob Agents Chemother; 1983 Aug; 24(2):252-61. PubMed ID: 6685452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.
    Lunell E; Borgå O; Larsson R
    Eur J Clin Pharmacol; 1984; 26(1):87-93. PubMed ID: 6714295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis.
    Lehmann CR; Heironimus JD; Collins CB; O'Neil TJ; Pierson WP; Crowe JT; Melikian AP; Wright GJ
    Clin Pharmacol Ther; 1985 Mar; 37(3):284-9. PubMed ID: 3971652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.
    Webb DB; Roberts DE; Williams JD; Asscher AW
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():83-7. PubMed ID: 3804907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of carteolol in patients with impaired renal function.
    Amemiya M; Tabei K; Furuya H; Sakairi Y; Asano Y
    Eur J Clin Pharmacol; 1992; 43(4):417-21. PubMed ID: 1451723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients.
    Milne RW; Nation RL; Somogyi AA; Bochner F; Griggs WM
    Br J Clin Pharmacol; 1992 Jul; 34(1):53-9. PubMed ID: 1633068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excretion pathways of amphotericin B.
    Craven PC; Ludden TM; Drutz DJ; Rogers W; Haegele KA; Skrdlant HB
    J Infect Dis; 1979 Sep; 140(3):329-41. PubMed ID: 501147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis.
    Singlas E; Pioger JC; Taburet AM; Colin JN; Fillastre JP
    Clin Pharmacol Ther; 1989 Aug; 46(2):190-7. PubMed ID: 2758728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH; van Brummelen P; van Harten J; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of advanced age on the disposition of acetazolamide.
    Chapron DJ; Sweeney KR; Feig PU; Kramer PA
    Br J Clin Pharmacol; 1985 Mar; 19(3):363-71. PubMed ID: 3986087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nizatidine disposition in subjects with normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Bopp RJ; Sloan RS; Callaghan JT
    Clin Pharmacol Ther; 1988 Jun; 43(6):688-95. PubMed ID: 2897890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment.
    Viani A; Rizzo G; Carrai M; Pacifici GM
    Br J Clin Pharmacol; 1992 Mar; 33(3):299-304. PubMed ID: 1576051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of temocillin in patients with normal and impaired renal function.
    Boelaert J; Daneels R; Schurgers M; Lambert AM; Van Landuyt HW; Mellows G; Wolf J; Swaisland AJ
    J Antimicrob Chemother; 1983 Apr; 11(4):349-56. PubMed ID: 6853404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.